Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

(2020) Maria M. Posada et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB

(2020) Qing-Yun Chong et al.   PHARMACOLOGICAL RESEARCH

Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application

(2020) Pooja Dhakne et al.   BIOMEDICAL CHROMATOGRAPHY

Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report

(2020) Akimitsu Maeda et al.   INVESTIGATIONAL NEW DRUGS

Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation

(2019) Adnan A. Kadi et al.   Royal Society Open Science

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry

(2019) Alejandra Martínez-Chávez et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Update on Metabolism of Abemaciclib: In Silico , In vitro and In vivo Metabolite Identification and Characterization using High Resolution Mass spectrometry

(2019) Disha Thakkar et al.   Drug Testing and Analysis

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS